Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer

Yoshio Maki, Tomoyasu Tsushima, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Ohmori, Toyoko Tanahashi, Katsuichi Nanba, Teruhisa Ohashi, Katsuyoshi Kondo, Takashi Saika, Toshihiko Asahi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

(Purpose) There is no effective therapy against hormone refractory prostate cancer. This led us to evaluate the effectiveness and toxicity of cis-platinum (CDDP) and ifosfamide (IFM) combination chemotherapy in the patients with hormone-unresponsive carcinoma of the prostate. (Methods) Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1.2 g/m2/day intravenously on day 1 through day 5 of 28-day cycle. (Results) Twenty seven patients with hormone unresponsive prostate cancer were enrolled onto this trial. Of these patients, seven (26%) demonstrated a partial objective response (PR), and ten (37%) a stable disease (ST). The response duration of PR cases lasted from 6 to 49 months with a median of 16 months and the response duration of PR+ST cases lasted from 3 to 36 months with a median of 10 months. Subjective improvement was obtained in 11 patients (41%). Survival duration of all cases were 4 to 89 months with a median of 23 months and probabilities of survival at 3 years and 5 years were 36% and 24%, respectively. The toxicity of this treatment was mostly mild to moderate, anemia (96%), leukocytopenia (89%), anorexia (81%), alopecia (67%), thrombocytopenia (44%), hematuria (38%), renal dysfunction (19%) and liver dysfunction (7%) were noticed. Severe toxicity was observed in two cases, one acute renal failure and one endotoxin shock. (Conclusion) We conclude that CDDP and IFM combination chemotherapy was active regimen for hormone unresponsive prostate cancer.

Original languageEnglish
Pages (from-to)657-664
Number of pages8
JournalJapanese Journal of Urology
Volume89
Issue number7
Publication statusPublished - Jul 1998

Fingerprint

Ifosfamide
Combination Drug Therapy
Cisplatin
Prostatic Neoplasms
Hormones
Survival
Alopecia
Leukopenia
Anorexia
Hematuria
Acute Kidney Injury
Endotoxins
Thrombocytopenia
Liver Diseases
Anemia
Prostate
Shock
Carcinoma
Kidney
Therapeutics

Keywords

  • Chemotherapy
  • Hormone refractory
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Maki, Y., Tsushima, T., Nasu, Y., Kumon, H., Ohmori, H., Tanahashi, T., ... Asahi, T. (1998). Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer. Japanese Journal of Urology, 89(7), 657-664.

Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer. / Maki, Yoshio; Tsushima, Tomoyasu; Nasu, Yasutomo; Kumon, Hiromi; Ohmori, Hiroyuki; Tanahashi, Toyoko; Nanba, Katsuichi; Ohashi, Teruhisa; Kondo, Katsuyoshi; Saika, Takashi; Asahi, Toshihiko.

In: Japanese Journal of Urology, Vol. 89, No. 7, 07.1998, p. 657-664.

Research output: Contribution to journalArticle

Maki, Y, Tsushima, T, Nasu, Y, Kumon, H, Ohmori, H, Tanahashi, T, Nanba, K, Ohashi, T, Kondo, K, Saika, T & Asahi, T 1998, 'Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer', Japanese Journal of Urology, vol. 89, no. 7, pp. 657-664.
Maki, Yoshio ; Tsushima, Tomoyasu ; Nasu, Yasutomo ; Kumon, Hiromi ; Ohmori, Hiroyuki ; Tanahashi, Toyoko ; Nanba, Katsuichi ; Ohashi, Teruhisa ; Kondo, Katsuyoshi ; Saika, Takashi ; Asahi, Toshihiko. / Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer. In: Japanese Journal of Urology. 1998 ; Vol. 89, No. 7. pp. 657-664.
@article{03301448a3a7405a918dbefb1624b242,
title = "Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer",
abstract = "(Purpose) There is no effective therapy against hormone refractory prostate cancer. This led us to evaluate the effectiveness and toxicity of cis-platinum (CDDP) and ifosfamide (IFM) combination chemotherapy in the patients with hormone-unresponsive carcinoma of the prostate. (Methods) Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1.2 g/m2/day intravenously on day 1 through day 5 of 28-day cycle. (Results) Twenty seven patients with hormone unresponsive prostate cancer were enrolled onto this trial. Of these patients, seven (26{\%}) demonstrated a partial objective response (PR), and ten (37{\%}) a stable disease (ST). The response duration of PR cases lasted from 6 to 49 months with a median of 16 months and the response duration of PR+ST cases lasted from 3 to 36 months with a median of 10 months. Subjective improvement was obtained in 11 patients (41{\%}). Survival duration of all cases were 4 to 89 months with a median of 23 months and probabilities of survival at 3 years and 5 years were 36{\%} and 24{\%}, respectively. The toxicity of this treatment was mostly mild to moderate, anemia (96{\%}), leukocytopenia (89{\%}), anorexia (81{\%}), alopecia (67{\%}), thrombocytopenia (44{\%}), hematuria (38{\%}), renal dysfunction (19{\%}) and liver dysfunction (7{\%}) were noticed. Severe toxicity was observed in two cases, one acute renal failure and one endotoxin shock. (Conclusion) We conclude that CDDP and IFM combination chemotherapy was active regimen for hormone unresponsive prostate cancer.",
keywords = "Chemotherapy, Hormone refractory, Prostate cancer",
author = "Yoshio Maki and Tomoyasu Tsushima and Yasutomo Nasu and Hiromi Kumon and Hiroyuki Ohmori and Toyoko Tanahashi and Katsuichi Nanba and Teruhisa Ohashi and Katsuyoshi Kondo and Takashi Saika and Toshihiko Asahi",
year = "1998",
month = "7",
language = "English",
volume = "89",
pages = "657--664",
journal = "Japanese Journal of Urology",
issn = "0021-5287",
publisher = "THE JAPANESE UROLOGICAL ASSOCIATION",
number = "7",

}

TY - JOUR

T1 - Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer

AU - Maki, Yoshio

AU - Tsushima, Tomoyasu

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Tanahashi, Toyoko

AU - Nanba, Katsuichi

AU - Ohashi, Teruhisa

AU - Kondo, Katsuyoshi

AU - Saika, Takashi

AU - Asahi, Toshihiko

PY - 1998/7

Y1 - 1998/7

N2 - (Purpose) There is no effective therapy against hormone refractory prostate cancer. This led us to evaluate the effectiveness and toxicity of cis-platinum (CDDP) and ifosfamide (IFM) combination chemotherapy in the patients with hormone-unresponsive carcinoma of the prostate. (Methods) Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1.2 g/m2/day intravenously on day 1 through day 5 of 28-day cycle. (Results) Twenty seven patients with hormone unresponsive prostate cancer were enrolled onto this trial. Of these patients, seven (26%) demonstrated a partial objective response (PR), and ten (37%) a stable disease (ST). The response duration of PR cases lasted from 6 to 49 months with a median of 16 months and the response duration of PR+ST cases lasted from 3 to 36 months with a median of 10 months. Subjective improvement was obtained in 11 patients (41%). Survival duration of all cases were 4 to 89 months with a median of 23 months and probabilities of survival at 3 years and 5 years were 36% and 24%, respectively. The toxicity of this treatment was mostly mild to moderate, anemia (96%), leukocytopenia (89%), anorexia (81%), alopecia (67%), thrombocytopenia (44%), hematuria (38%), renal dysfunction (19%) and liver dysfunction (7%) were noticed. Severe toxicity was observed in two cases, one acute renal failure and one endotoxin shock. (Conclusion) We conclude that CDDP and IFM combination chemotherapy was active regimen for hormone unresponsive prostate cancer.

AB - (Purpose) There is no effective therapy against hormone refractory prostate cancer. This led us to evaluate the effectiveness and toxicity of cis-platinum (CDDP) and ifosfamide (IFM) combination chemotherapy in the patients with hormone-unresponsive carcinoma of the prostate. (Methods) Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1.2 g/m2/day intravenously on day 1 through day 5 of 28-day cycle. (Results) Twenty seven patients with hormone unresponsive prostate cancer were enrolled onto this trial. Of these patients, seven (26%) demonstrated a partial objective response (PR), and ten (37%) a stable disease (ST). The response duration of PR cases lasted from 6 to 49 months with a median of 16 months and the response duration of PR+ST cases lasted from 3 to 36 months with a median of 10 months. Subjective improvement was obtained in 11 patients (41%). Survival duration of all cases were 4 to 89 months with a median of 23 months and probabilities of survival at 3 years and 5 years were 36% and 24%, respectively. The toxicity of this treatment was mostly mild to moderate, anemia (96%), leukocytopenia (89%), anorexia (81%), alopecia (67%), thrombocytopenia (44%), hematuria (38%), renal dysfunction (19%) and liver dysfunction (7%) were noticed. Severe toxicity was observed in two cases, one acute renal failure and one endotoxin shock. (Conclusion) We conclude that CDDP and IFM combination chemotherapy was active regimen for hormone unresponsive prostate cancer.

KW - Chemotherapy

KW - Hormone refractory

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=7344236787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7344236787&partnerID=8YFLogxK

M3 - Article

C2 - 9739587

AN - SCOPUS:7344236787

VL - 89

SP - 657

EP - 664

JO - Japanese Journal of Urology

JF - Japanese Journal of Urology

SN - 0021-5287

IS - 7

ER -